PolyPeptide Group informed about the course of business (German)

Baar, July 12, 2022 – PolyPeptide Group AG ^

PolyPeptide Group / Keywords: Semi-Annual Results / Profit Drop

The PolyPeptide group announced the course of its activity

12/07/2022 / 07:00 CET / CEST

The best jobs of the day

Find the best job offers now and
be notified by e-mail.

Publication of an ad hoc advertisement in accordance with Art. 53 LR

The issuer / publisher is responsible for the content of the application.

————————————————– —————————————

Publication for the media – Ad hoc publication pursuant to Art. 53 of the CoR

PolyPeptide informed about the course of business

Baar, July 12, 2022 – PolyPeptide Group AG (PolyPeptide), global

a leading contract developer and producer of peptides and

Oligonucleotides, informed about the course of the activity. during this

The company continues the implementation of its development strategy

invested, expects a lower profit in the first half of 2022.

compared to the first half of 2021. EBITDA margin for the first half of the year

Mid-2022 is expected to account for around 20% of sales.

Development comes from a combination of factors. Down

firstly, sales in the first half of 2022 will be approximately at the level

the same period last year, but the business mix was exceptional then

cheap. In addition, PolyPeptide was able to increase the cost of raw materials,

We are not yet handing over energy, consumables and wages to our customers.

Finally, PolyPeptide has an organization to grow

further expansion of the business and the average number

employees (full-time equivalents) compared to June 2021 via

Increase of approximately 13% in all production sites.

Moreover, PolyPeptide is looking forward to the current development

The coronavirus pandemic has postponed part of the schedule to 2022.

Pending sales related to COVID-19 by 2023 PolyPeptide will be

further details on the results for the first half of 2022 i

Outlook update for the financial year 2022, scheduled for April 19

Planned semi-annual report for August 2022.

PolyPeptide focuses on a strategic growth program to …

long-term potential for core activities with peptides and oligonucleotides

realize. On the one hand, the company invests in the other

Extending the possibilities of handling customer projects in the clinical phase III

Development. On the other hand, it strives for constant expansion

its funnel, with a backlog of 181 active customer projects at the end

June 2021 may be increased to 218 projects by the end of June 2022.

contact

PolyPeptide Group AG

Michael Stäheli, director of investor relations and corporate communications

[email protected]+41 41 723 20 34

About Polypeptide

PolyPeptide is a contract developer and manufacturer (CDMO) in the field

Proprietary and generic GMP grade peptides manufactured by the pharmaceutical company i

Biotech company in approved pharmaceutical products, drugs

in clinical development and generics. This

The company, which dates back to 1952, today makes approx

half of all currently approved peptide active ingredients and has

global reach with six GMP-certified manufacturing sites in

Europe, USA and India. As an international company with around 1100

employees by the end of 2021 PolyPeptide combines comprehensive knowledge and

Experience. PolyPeptide is organic and through selective acquisitions

existing knowledge and is currently a leading company in

peptide production outsourcing. PolyPeptide Shares (SIX: PPGN)

are listed on the SIX Swiss Exchange. For more information, see

on the website polieptyd.com.

@PolyPeptide – Follow us on LinkedIn

Forward-Looking Information Notice

This press release was prepared and includes PolyPeptide Group AG

forward-looking information and statements

Group business prospects. These statements are based on the current statements

Expectations, estimates and forecasts about the factors that

may affect the company’s future results. This

Generally, expectations, estimates and projections are related to the statements

recognize words such as “expect”, “believe”, “evaluate”, “aim”,

“Plan”, “perspective” or similar expressions. There are many of them

Risks, uncertainties, and other factors, many of which are beyond

are under the control of PolyPeptide Group AG, which may result in:

the actual results of the group differ significantly from those on this one

the press release contained information and forward-looking statements

vary, which can affect the group’s ability to:

achieve the set goals. Among the important factors leading to such

Deviations may include, but are not limited to: Relationships with

employees, customers and other business partners; strategies

competitors; production capacity and use; quality defects;

supply chain matters; legal, tax or

regulatory disputes; and changes in policy

the social and regulatory environment in which the Group operates,

or relating to economic or technological development or

Conditions. Although PolyPeptide Group AG assumes that their

Expectations reflected in such forward-looking statements

based on reasonable assumptions, cannot guarantee that

these expectations are actually met.

Alternative Financial Performance Measures (APM)

This press release contains references to operational indicators,

for example, active customer projects and APMs that are not covered by IFRS

are defined or determined, including EBITDA. They should be like

supplementary information to the group’s consolidated financial results

based on IFRS and not as a substitute for it. She

may not match similarly named other people’s metrics

comparable companies. Agent definitions

You can find pointers and APMs, including relevant shortcuts

in the “Definitions and arrangements” section of the 2021 Annual Report and

Bi-annual report 2022 (once published) by PolyPeptide Group AG.

————————————————– —————————————

End of ad hoc announcement

————————————————– —————————————

German

Company: PolyPeptide Group

Neuhofstraße 24

6340 Baars

Switzerland

Telephone: +41 417 232 040

E-mail: [email protected]

Web: www.polipeptide.com

ISIN: CH1110760852

Security number: 111076085

Exchanges: SIX Swiss Exchange

EQS message ID: 1395563

End of news EQS news service

————————————————– —————————————

1395563 07/12/2022 CET / CEST

°

Leave a Comment